AstraZeneca pays $1.3bn for gout-buster drug
The burst of M&A activity in the pharmaceuticals industry continued yesterday when AstraZeneca announced a $1.26bn (£783m) deal to buy the US company Ardea Biosciences, which is working on a new medicine to battle gout.
Astra, Britain's second-biggest drugmaker, is facing a patent cliff, as lucrative blockbusters including its antipsychotic Seroquel begin to face generic competition, while several medicines in its pipeline have failed at late-stage trials.
Shareholders will hope the deal to buy California's Ardea for $32 a share – 54 per cent above its closing share price on Friday – will bolster Astra's prospects. Ardea's Lesinurad is in late-stage development as a potential treatment for chronic gout, which is expected to affect almost 17 million people by 2019.
David Brennan, AstraZeneca's chief executive, said: "The Ardea team has done a great job developing Lesinurad along with a promising next-generation gout programme. These compounds have real potential to benefit patients."
The Microsoft mogul told fans a few home truths during his Reddit AMA
- 1 Woman falls to her death as she celebrates marriage proposal at the edge of Ibiza cliff
- 3 Ball pool for adults opens in London
- 4 Baldness could soon be treated using stem cells, scientists hope
- 5 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
Woman falls to her death as she celebrates marriage proposal at the edge of Ibiza cliff
Boris Johnson claims porn-obsessed Islamic jihadists are 'literally w*****s'
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
Teenager brandishing fake gun taken down by police after demanding airtime on Netherlands' NOS TV station
Ball pool for adults opens in London
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
iJobs Money & Business
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...